Skip to main content

Vismodegib User Reviews & Ratings

Brand names: Erivedge

Vismodegib has an average rating of 9.0 out of 10 from a total of 2 reviews on Drugs.com. 100% of reviewers reported a positive experience, while 0% reported a negative experience.

Condition Avg. Rating Reviews Compare
Basal Cell Carcinoma
9.0
2 reviews for Basal Cell Carcinoma 7 medications

Write a review

  • Bad...
  • Taken for 1 to 6 months
  • January 23, 2020

For Basal Cell Carcinoma "During treatment: hair loss, severe muscle cramps, weakness and fatigue, rapid weight loss, 55 pounds in 5 months. Three years after stopping drug treatment: hair returned but remains very thin. Must drink lots of water or muscle cramps return. Weight loss continues, started at 275 pounds and size 46 pants, last checkup 165 pounds size 30 pants, weight loss has slowed but continues approximately 2 pounds per month while maintaining a healthy diet. Male started treatment at 59 years old. Now in very good health with minimal exercise. 1/23/2020."

9 / 10
Was this helpful?YesNo
24 Report
  • Pap...
  • Taken for 10 years or more
  • August 4, 2022

For Basal Cell Carcinoma "Category: Patient. Tumor location: I have Basal Cell Nevus Syndrome, pecs and scapula to crown of head, predominantly on left side of face. Tumors too numerous to count. Mohs surgeries continued concurrent with dosing. I was an original participant in Phase 1 clinical trial of Erivedge. Participated from Phase 1 through FDA approval. Dosed from Nov. 2007 through March 2020. First observation of tumor shrinkage late March/early April 2008. From that time, for a time, saw an acceleration of tumor shrinkage, involution, and 'disappearance' with approximately 80% of tumors. Side effects: Severe muscle cramps, muscle spasms, loss of hair, beard, eyebrows, eyelashes, and body hair. Medicine worked well until roughly 2017. Noticed regrowth or new growth in or about same locations where tumors previously affected by Erivedge were located. Attending physicians have commented that the cancer cells, over time, can 'smarten up' to a molecular therapy, making said therapy less effective, but with each case being unique to the patient."

9 / 10
Was this helpful?YesNo
3 Report

Are you taking this medicine?

Your review helps others make informed decisions.
Write a review
Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.